Figure 1. Monoclonal antibodies (MAbs) are expected to dominate the future biopharmaceutical landscape (1). Although chromatography is the mainstay of MAb downstream purification processes, more efficient and cost-effective chromatography technologies are needed to address increasing MAb titers in mammalian cell culture supernatants. Ion-exchange membrane chromatography has been demonstrated to capture large biomolecules such as viruses and plasmid DNA with higher dynamic binding capacity than ion-exchange beaded column chromatography (2, 3). Recently, anion-exchange membrane chromatography has been viewed as a viable…